This website contains promotional content and is intended for Healthcare Professionals based in the United Kingdom only. Some content is only relevant to HCPs practising in Great Britain (England, Scotland, Wales). This website is optimised for desktop use, and some features may perform differently on mobile devices.

Adverse event reporting can be found at the bottom of the page.

Campus
  1. Article
  2. Source: Campus Sanofi
  3. 20 Sept 2023
13 min

Independent UK Real World Data. Data from 107 patients from 24 centres across the UK.

Author: Sanofi

Presented by Professor Basu and Dr Ramasamy

  

This is intended for HCPs practising in Great Britain (England, Scotland, Wales) only.

Prescribing Information for SARCLISA®▼ (isatuximab) can be found via the Product Card at the bottom of the page.

In this video, you'll learn about

An independent UK real world study presented by Professor Basu and Dr Ramasamy. This data was generated across 24 centres including 107 patients, and demonstrated that SARCLISA® + Pd is effective and achievable in routine clinical care with outcomes comparable to those seen in the phase 3 ICARIA-MM trial.1,2

Overview of SARCLISA®

Find out more about SARCLISA® + Pd efficacy and safety data and dosing information.

Dosing and Administration Guide

Download a handy guide to SARCLISA dosing and administration information

Patient Booklet

Download SARCLISA® patient information.

1/3

Overview of SARCLISA®

Find out more about SARCLISA® + Pd efficacy and safety data and dosing information.

Dosing and Administration Guide

Download a handy guide to SARCLISA dosing and administration information

Patient Booklet

Download SARCLISA® patient information.

Get in touch with the Oncology Team

Relapsed Refractory Multiple Myeloma Product

Sarclisa logo GB only

Learn more  →

Prescribing information GB

MAT-XU-2202578 (v4.0)
Date of preparation: June 2024

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

References

  1. Attal M, et al. Lancet. 2019;394:2096–107.

  2. Djebbari F, et al. Hemasphere. 2022;6(6):e738.

MAT-XU-2202566 (v3.0) Date of Preparation: June 2024